Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less ... more

• Amblyopia Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 30
  Amblyopia Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Amblyopia Global Clinical Trials Review, Q1, 2011" provides data on the Amblyopia clinical trial scenario....

• Cerebrovascular Disease Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 32
  Cerebrovascular Disease Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Cerebrovascular Disease Global Clinical Trials Review, Q1, 2011" provides data on the Cerebrovascular...

• Asperger Syndrome Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 36
  Asperger Syndrome Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Asperger Syndrome Global Clinical Trials Review, Q1, 2011" provides data on the Asperger Syndrome...

• Cerebral Hypoxia Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 38
  Cerebral Hypoxia Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Cerebral Hypoxia Global Clinical Trials Review, Q1, 2011" provides data on the Cerebral Hypoxia...

• Other Central Nervous System Disorders Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 75
  Other Central Nervous System Disorders Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Other Central Nervous System Disorders Global Clinical Trials Review, Q1,...

• Drug Abuse Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 68
  Drug Abuse Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Drug Abuse Global Clinical Trials Review, Q1, 2011" provides data on the Drug Abuse clinical trial scenario....

• Brain Injury Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 58
  Brain Injury Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Brain Injury Global Clinical Trials Review, Q1, 2011" provides data on the Brain Injury clinical trial...

• Cancer Pain Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 71
  Cancer Pain Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Cancer Pain Global Clinical Trials Review, Q1, 2011" provides data on the Cancer Pain clinical trial...

• Cerebellar Ataxia Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 25
  Cerebellar Ataxia Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Cerebellar Ataxia Global Clinical Trials Review, Q1, 2011" provides data on the Cerebellar Ataxia...

• Other Pain Disorders Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 67
  Other Pain Disorders Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Other Pain Disorders Global Clinical Trials Review, Q1, 2011" provides data on the Other Pain...

• Brain Disease Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 31
  Brain Disease Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Brain Disease Global Clinical Trials Review, Q1, 2011" provides data on the Brain Disease clinical...

• Major Depressive Disorder - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 91
  Major Depressive Disorder - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Major Depressive Disorder - Pipeline Review, Q1 2011', provides an overview of the Major Depressive Disorder...

• Amyotrophic Lateral Sclerosis - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 69
  Amyotrophic Lateral Sclerosis - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Amyotrophic Lateral Sclerosis - Pipeline Review, Q1 2011', provides an overview of the Amyotrophic Lateral...

• Schizophrenia - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 134
  Schizophrenia - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Schizophrenia - Pipeline Review, Q1 2011', provides an overview of the Schizophrenia therapeutic pipeline. This report provides...

• Bipolar Depression - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 83
  Bipolar Depression - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Bipolar Depression - Pipeline Review, Q1 2011', provides an overview of the Bipolar Depression therapeutic pipeline....

• Migraine - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 86
  Migraine - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Migraine - Pipeline Review, Q1 2011', provides an overview of the Migraine therapeutic pipeline. This report provides information...

• Acute Ischemic Stroke - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 61
  Acute Ischemic Stroke - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Acute Ischemic Stroke - Pipeline Review, Q1 2011', provides an overview of the Acute Ischemic Stroke therapeutic...

• Smoking Addiction - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 75
  Smoking Addiction - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Smoking Addiction - Pipeline Review, Q1 2011', provides an overview of the Smoking Addiction therapeutic pipeline. This...

• Huntingtons Disease - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 57
  Huntingtons Disease - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Huntingtons Disease - Pipeline Review, Q1 2011', provides an overview of the Huntingtons Disease therapeutic pipeline....

• Insomnia - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 62
  Insomnia - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Insomnia - Pipeline Review, Q1 2011', provides an overview of the Insomnia therapeutic pipeline. This report provides information...

• Neuropathic Pain - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 116
  Neuropathic Pain - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Neuropathic Pain - Pipeline Review, Q1 2011', provides an overview of the Neuropathic Pain therapeutic pipeline. This...

• Epilepsy - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 85
  Epilepsy - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Epilepsy - Pipeline Review, Q1 2011', provides an overview of the Epilepsy therapeutic pipeline. This report provides information...

• Autism - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 52
  Autism - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Autism - Pipeline Review, Q1 2011', provides an overview of the Autism therapeutic pipeline. This report provides information on...

• Fibromyalgia - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 40
  Fibromyalgia - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Fibromyalgia - Pipeline Review, Q1 2011', provides an overview of the Fibromyalgia therapeutic pipeline. This report provides...

• Osteoarthritis Pain - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 60
  Osteoarthritis Pain - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Osteoarthritis Pain - Pipeline Review, Q1 2011', provides an overview of the Osteoarthritis Pain therapeutic pipeline....

• Other Psychiatric Disorders Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 76
  Other Psychiatric Disorders Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Other Psychiatric Disorders Global Clinical Trials Review, Q1, 2011" provides data...

• Other Neurologic Disorders Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 72
  Other Neurologic Disorders Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Other Neurologic Disorders Global Clinical Trials Review, Q1, 2011" provides data on...

• Mental Illness Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 55
  Mental Illness Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Mental Illness Global Clinical Trials Review, Q1, 2011" provides data on the Mental Illness clinical...

• Spinal Cord Injury Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 56
  Spinal Cord Injury Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Spinal Cord Injury Global Clinical Trials Review, Q1, 2011" provides data on the Spinal Cord...

• Neuroblastoma Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 62
  Neuroblastoma Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Neuroblastoma Global Clinical Trials Review, Q1, 2011" provides data on the Neuroblastoma clinical...

• Tropical Spastic Paraparesis Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 25
  Tropical Spastic Paraparesis Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Tropical Spastic Paraparesis Global Clinical Trials Review, Q1, 2011" provides data...

• Back Pain Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 70
  Back Pain Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Back Pain Global Clinical Trials Review, Q1, 2011" provides data on the Back Pain clinical trial scenario....

• Anorexia Nervosa Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 46
  Anorexia Nervosa Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Anorexia Nervosa Global Clinical Trials Review, Q1, 2011" provides data on the Anorexia Nervosa...

• Aphasia Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 32
  Aphasia Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Aphasia Global Clinical Trials Review, Q1, 2011" provides data on the Aphasia clinical trial scenario....

• Delirium Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 42
  Delirium Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Delirium Global Clinical Trials Review, Q1, 2011" provides data on the Delirium clinical trial scenario....

• Brain Infarction Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 39
  Brain Infarction Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Brain Infarction Global Clinical Trials Review, Q1, 2011" provides data on the Brain Infarction...

• Ataxia-Telangiectasia [Louis-Bar syndrome] Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 30
  Ataxia-Telangiectasia [Louis-Bar syndrome] Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Ataxia-Telangiectasia [Louis-Bar Syndrome] Global Clinical Trials Review,...

• Acute Pain - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 61
  Acute Pain - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Acute Pain - Pipeline Review, Q1 2011', provides an overview of the Acute Pain therapeutic pipeline. This report provides information...

• Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, Q1 2011

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Feb 2011 , Pages: 58
  Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, Q1 2011', provides an...

• Biomarkers in Alzheimer's Disease - 2011

  EURO€ 1,771.00USD$ 2,304.00GBP£ 1,490.00AUD$ 2,254.00JPY¥ 227,484.00SEK 15 128,00CHF 2'172.00CAD$ 2,348.00 BioPharm Reports (VennBio Ltd.), Feb 2011 , Pages: 137
  This report provides an overview of biomarkers associated with Alzheimer's disease (AD) that have potential in differential diagnosis, in following treatment, in clinical trials and drug discovery These...

• Restless Legs Syndrome Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 60
  Restless Legs Syndrome Global Clinical Trials Review, Q1, 2011 Summary Our clinical trial report, “Restless Legs Syndrome Global Clinical Trials Review, Q1, 2011" provides data on the Restless Legs...

• Friedreich Ataxia Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 37
  Friedreich Ataxia Global Clinical Trials Review, Q1, 2011 Summary Our clinical trial report, “Friedreich Ataxia Global Clinical Trials Review, Q1, 2011" provides data on the Friedreich Ataxia clinical...

• Psychogenic Movement Disorders Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 26
  Psychogenic Movement Disorders Global Clinical Trials Review, Q1, 2011 Summary Our clinical trial report, “Psychogenic Movement Disorders Clinical Trials Review, Q1, 2011" provides data on the Psychogenic...

• Non Erosive Reflux Disease (NERD) Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Feb 2011 , Pages: 22
  Non Erosive Reflux Disease (NERD) Global Clinical Trials Review, Q1, 2011 Summary Our clinical trial report, “Non Erosive Reflux Disease (NERD)Global Clinical Trials Review, Q1, 2011" provides data...

• Pain Management Review and Outlook 2011

  EURO€ 319.00USD$ 415.00GBP£ 268.00AUD$ 406.00JPY¥ 40,974.00SEK 2 725,00CHF 391.00CAD$ 423.00 UBM Canon, Feb 2011 , Pages: 68
  Industry analysts estimate that more than 1 5 billion people around the world suffer from chronic pain, making it the number one reason patients seek medical care In fact, studies have shown that pain...

• Schizophrenia Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Jan 2011 , Pages: 94
  Schizophrenia Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Schizophrenia Global Clinical Trials Review, Q1, 2011" provides data on the Schizophrenia clinical...

• Depression Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Jan 2011 , Pages: 77
  Depression Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Depression Global Clinical Trials Review, Q1, 2011" provides data on the Depression clinical trial scenario....

• Pain Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Jan 2011 , Pages: 77
  Pain Global Clinical Trials Review, Q1, 2011 Summary GlobalData's clinical trial report, “Pain Global Clinical Trials Review, Q1, 2011" provides data on the Pain clinical trial scenario. This report...

• Migraine Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Jan 2011 , Pages: 74
  Migraine Global Clinical Trials Review, Q1, 2011 Summary Our clinical trial report, “Migraine Global Clinical Trials Review, Q1, 2011" provides data on the Migraine clinical trial scenario This report...

• Sleep Disorders Global Clinical Trials Review, Q1, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Jan 2011 , Pages: 72
  Sleep Disorders Global Clinical Trials Review, Q1, 2011 Summary Our clinical trial report, “Sleep Disorders Global Clinical Trials Review, Q1, 2011" provides data on the Sleep Disorders clinical trial...